Manuscripts
Showing 1572 manuscripts.
Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries
Citation
L Barlow-Mosha, H Ruisenor-Escudero, B Laughton, C Joyce, L Fairlie, V Tichaona, P Kamthunzi, B Zimmer, K McCarthy, M Boivin, I Familiar, M Chernoff. Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries. AIDS Care. 2020. 32: 486-494. PMID: 31462095Year
          2020      
Journal
          AIDS Care      
Study
          P1104s      
Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions
Citation
Pat Flynn, Anne Coletti, Katie McCarthy, Renee Browning, James McIntyre, Sean S Brummel, David E Shapiro, Camlin Tierney, PROMISE study team, Konstantia Angelidou, Mary Glenn Fowler. Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions. Clinical Trials. 2020. 17: 437-447. PMID: 32191142Year
          2020      
Journal
          Clinical Trials      
Study
          1077HS,          1077BF,          1077FF      
Streptococcus pneumoniae colonization in pneumococcal vaccine-naïve HIV-exposed infected and -uninfected South African children
Citation
P Adrian, B Zeldow, A Violari, S Dittmer, H Cassim, T Thomas, N van Niekerk, M Cotton, C Mitchell, S Madhi on behalf of the P1041 team, M Nunes, S Kim. Streptococcus pneumoniae colonization in pneumococcal vaccine-naïve HIV-exposed infected and -uninfected South African children. Medicine. 2020. 99: e19353. PMID: 32118776Year
          2020      
Journal
          Medicine      
Study
          P1041      
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial
Citation
Blandina Theophil Mmbaga, Katie McCarthy, Konstantia Angelidou, Judith S Currier, Lee Fairlie, Mary Glenn Fowler, Avy Violari, 1077BF/1077FF PROMISE Team, Gerhard Theron, Cornelius Mukuzunga, Sajeeda Mawlana, Mwangelwa Mubiana-Mbewe, Megeshinee Naidoo, Bonus Makanani, Patricia Mandima, Teacler Nematadzira, Nishi Suryavanshi, Tapiwa Mbengeranwa, Patience Atuhaire, Amy Lofits, Sean S Brummel, Michael Basar. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial. PLoS One. 2020. 15: e0228003. PMID: 31999753Year
          2020      
Journal
          PLoS One      
Study
          1077BF,          1077FF      
Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children
Citation
P Muresan, C Luongo, C Cunningham, P Collins, J Libous, U Buchholz, C Perlowski, IMPAACT 2011 Study Team, B Thumar, D Gnanashanmugam, J Moye, E Schappell, E Barr, V Rexroad, L Fearn, S Spector, M Aziz, M Cielo, E McFarland, C Beneri, R Karron, A Wiznia. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. Journal of Infectious Diseases. 2020. 221: 534-543. PMID: 31758177Year
          2020      
Journal
          Journal of Infectious Diseases      
Study
          IMPAACT 2011      
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial
Citation
Mark Mirochnick, Patricia M Flynn, Kevin Butler, Jennifer J Kiser, George K Siberry, Terry Fenton, Mae Cababasay, Mary G Fowler, PROMISE Study Team, Jim Aizire, Kristina Brooks. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Journal of Acquired Immune Deficiency Syndromes. 2020. 83: 173-180. PMID: 31929405Year
          2020      
Journal
          Journal of Acquired Immune Deficiency Syndromes      
Study
          1077BF      
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
Citation
D Yin, C Ludema, S Cole, C Golin, W Miller, M Warshaw, R McKinney ; on behalf of the PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS One. 2020. 15: e0242405. PMID: 33226999Year
          2020      
Journal
          PLoS One      
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)
  
  
    Citation
Mae Cababasay, Jiajia Wang, Anne Chain, Hedy Teppler, Stephanie Popson, Bobbie Graham, Betsy Smith, Rohan Hazra, Kat Calabrese, Yvonne Bryson, Stephen Spector, Jos Lommerse, Mark Mirochnick, IMPAACT P1110 Protocol Team, Diana Clarke, Edward Acosta. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 2020. 84: 70-7. PMID: 31913995Year
          2020      
Journal
          Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology      
Study
          P1110      
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy
Citation
Khadija Amin, David E Shapiro , Alice Stek , Elizabeth Smith, Nahida Chakhtoura, Michael Basar, Kathleen George, Katherine M Knapp, Esaú C João, Kittipong Rungruengthanakit , Edmund Capparelli, Sandra Burchett , Mark Mirochnick , Brookie M Best, Ahizechukwu C Eke, P1026s Protocol Team, Jiajia Wang. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrobial Agents and Chemotherapy. 2020. 64: e02260-19. PMID: 32015036Year
          2020      
Journal
          Antimicrobial Agents and Chemotherapy      
Study
          P1026S      
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
Citation
Zaakirah Essack , David E Shapiro, Timothy R Cressey, Nahida Chakhtoura, Kulkanya Chokephaibulkit, Maria Isabel S Gouvèa, Peerawong Werarak, Maria de Lourdes B Teixeira, Lauren Laimon, Trevon L Fuller, Roslyn Hennessy , Blandina T Mmbaga, Lisa M Frenkel , James S Ngocho, Patricia Anthony, Boniface N Njau, Brookie M Best, Avy Violari, George K Siberry, Ruth Mathiba, Mark Mirochnick, Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Esaú C João, Pedro Cahn, R Leavitt Morrison, Sinart Prommas. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020. 7: e322-e331. PMID: 32386720Year
          2020      
Journal
          Lancet HIV      
Study
          P1081